BR112015022025A8 - composição e uso de um agente ativo - Google Patents

composição e uso de um agente ativo Download PDF

Info

Publication number
BR112015022025A8
BR112015022025A8 BR112015022025A BR112015022025A BR112015022025A8 BR 112015022025 A8 BR112015022025 A8 BR 112015022025A8 BR 112015022025 A BR112015022025 A BR 112015022025A BR 112015022025 A BR112015022025 A BR 112015022025A BR 112015022025 A8 BR112015022025 A8 BR 112015022025A8
Authority
BR
Brazil
Prior art keywords
infections
composition
subungual
diseases
active agent
Prior art date
Application number
BR112015022025A
Other languages
English (en)
Other versions
BR112015022025A2 (pt
Inventor
Lerman Bruce
E Birnbaum Jay
Original Assignee
Hallux Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hallux Inc filed Critical Hallux Inc
Publication of BR112015022025A2 publication Critical patent/BR112015022025A2/pt
Publication of BR112015022025A8 publication Critical patent/BR112015022025A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0069—Devices for implanting pellets, e.g. markers or solid medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Materials For Medical Uses (AREA)

Abstract

resumo método de tratamento de infecções, doenças ou desordens de unidade de unha os métodos para o tratamento subungueal de doenças ou desordens do aparelho prego, incluindo infecções, especialmente infecções fúngicas das unhas, psoríase e envolvendo as unhas dos pés e das mãos encontram-se descritos. os métodos de proporcionar uma técnica para a colocação de uma composição de droga contendo subungueal à redução do risco de formação de hematoma e melhorou o conforto do paciente.
BR112015022025A 2013-03-14 2014-03-07 composição e uso de um agente ativo BR112015022025A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784065P 2013-03-14 2013-03-14
US201361877229P 2013-09-12 2013-09-12
PCT/US2014/021786 WO2014159060A1 (en) 2013-03-14 2014-03-07 Method of treating infections, diseases or disorders of nail unit

Publications (2)

Publication Number Publication Date
BR112015022025A2 BR112015022025A2 (pt) 2017-07-18
BR112015022025A8 true BR112015022025A8 (pt) 2019-12-10

Family

ID=50349975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022025A BR112015022025A8 (pt) 2013-03-14 2014-03-07 composição e uso de um agente ativo

Country Status (10)

Country Link
US (3) US9498612B2 (pt)
EP (1) EP2968886A1 (pt)
JP (1) JP2016514024A (pt)
CN (1) CN105377355A (pt)
AU (1) AU2014241396A1 (pt)
BR (1) BR112015022025A8 (pt)
CA (1) CA2904703A1 (pt)
CL (1) CL2015002560A1 (pt)
RU (1) RU2015143995A (pt)
WO (1) WO2014159060A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904703A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
CN109310527A (zh) * 2016-02-09 2019-02-05 鲁玛治疗公司 用于通过光疗法来治疗牛皮癣的方法、组合物和设备
US20180092840A1 (en) * 2016-10-04 2018-04-05 The George Washington University Ultrasound-enhanced drug delivery for treatment of onychomycosis
TR201803213A2 (tr) * 2018-03-06 2018-04-24 Tambay Taskin Psori̇asi̇s tedavi̇si̇ i̇çi̇n pi̇mekroli̇mus, klobetazol ve kalsi̇potri̇ol i̇çeren topi̇kal farmasöti̇k formülasyonlar

Family Cites Families (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4186196A (en) 1976-04-19 1980-01-29 Lasher Edward Abe Topical anti-fungicide preparation
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4263289A (en) 1978-04-05 1981-04-21 Syntex (U.S.A.) Inc. Thio etianic acid derivatives
US4267179A (en) 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4180058A (en) 1978-08-15 1979-12-25 Jacob Brem Method of treating pathological conditions of the nail
US4250164A (en) 1979-04-09 1981-02-10 Bernstein Joel E Method of treating psoriasis of the nails and composition
DE19975055I1 (de) 1979-08-22 2000-01-27 Novartis Ag Propenylamine Verfahren zu ihrer Herstellung sie enthaltende pharmazeutische Zusammensetzungen und ihre Verwending als Arzneimittel
DE3262386D1 (en) 1981-06-06 1985-03-28 Pfizer Ltd Antifungal agents, processes for their preparation, and pharmaceutical compositions containing them
SU1122323A1 (ru) 1982-05-26 1984-11-07 Научно-Исследовательская Лаборатория Металлоостеосинтеза С Клиникой Им.А.Сеппо Способ лечени остеомиелита
US4490395A (en) 1983-04-18 1984-12-25 Warner-Lambert Company Chewing gum with improved stability
JPS59222406A (ja) 1983-06-01 1984-12-14 Teijin Ltd 歯周疾患治療用製剤及びその製造法
US4685883A (en) 1983-09-12 1987-08-11 Jernberg Gary R Local delivery of chemotherapeutic agents for the treatment of periodontal disease
US4892736A (en) 1983-10-07 1990-01-09 The Forsyth Dental Infirmary For Children Intra-pocket drug delivery devices for treatment of periodontal diseases
US4636520A (en) 1984-07-16 1987-01-13 Fujisawa Pharmaceutical Co., Ltd. Antifungal composition employing pyrrolnitrin in combination with an imidazole compound
US4568536A (en) 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
DE3544983A1 (de) 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
US4780320A (en) 1986-04-29 1988-10-25 Pharmetrix Corp. Controlled release drug delivery system for the periodontal pocket
US4919939A (en) 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
IL78826A (en) 1986-05-19 1991-05-12 Yissum Res Dev Co Precursor composition for the preparation of a biodegradable implant for the sustained release of an active material and such implants prepared therefrom
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5547988B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Alleviating signs of dermatological aging with glycolic acid lactic acid or citric acid
US5002769A (en) 1987-03-13 1991-03-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for the sustained-release of chlorhexidine
DE3720147A1 (de) 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
US5002938A (en) 1988-03-21 1991-03-26 Bristol-Myers Squibb Company Antifungal gel formulations
US5110809A (en) 1988-03-21 1992-05-05 Bristol-Myers Squibb Company Antifungal gel formulations
US5324520A (en) 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
CA2008775C (en) 1989-02-24 1998-12-22 Alberto Ferro Nail lacquer
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5219877A (en) 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
US5059123A (en) 1990-05-14 1991-10-22 Jernberg Gary R Periodontal barrier and method for aiding periodontal tissue regeneration
US5197882A (en) 1990-05-14 1993-03-30 Gary R. Jernberg Periodontal barrier and method for aiding periodontal tissue regeneration agents
US5063049A (en) 1990-06-11 1991-11-05 Calvert Billings Disinfectant nail polish remover
EP0489743A1 (en) 1990-07-03 1992-06-17 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
FR2673537B1 (fr) 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
DE4212105A1 (de) 1992-04-10 1993-10-14 Roehm Pharma Gmbh Nagellack zur Behandlung von Onychomykosen
RU2062607C1 (ru) 1992-09-28 1996-06-27 Медико-санитарная часть Государственного производственного объединения "Воткинский завод" Способ лечения ногтевого панариция
US5464610A (en) 1992-10-15 1995-11-07 Schering-Plough Healthcare Products, Inc. Method for treating onychomycosis
TW404844B (en) 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
DE19518262A1 (de) 1995-05-18 1996-11-21 Hoechst Ag Die Verwendung von Glyceryltriacetat zur Behandlung von Onychomykosen
US5916545A (en) 1993-07-28 1999-06-29 Pfizer Inc. Antifungal nail solution
US5391367A (en) 1993-07-28 1995-02-21 Pfizer Inc. Antifungal nail solution
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
RU2165265C2 (ru) 1993-10-07 2001-04-20 Одонтекс, Инк. Усилители абсорбции для фармацевтических композиций местного применения
US5487776A (en) 1994-03-17 1996-01-30 Nimni; Marcel Anti-fungal nail lacquer and method therefor
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
RU2083224C1 (ru) 1994-09-30 1997-07-10 Сергей Федорович Подчайнов Противогрибковое средство для стоп
US5641501A (en) 1994-10-11 1997-06-24 Ethicon, Inc. Absorbable polymer blends
KR960016882A (ko) 1994-11-01 1996-06-17 강재헌 치주염치료를 위한 서방출형 생분해성 제제
US5597849A (en) 1994-11-14 1997-01-28 Medical Polymer Technologies, Inc. Stick formulations for topical drug delivery of therapeutic agents and uses thereof
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5587152A (en) 1994-12-15 1996-12-24 Mackles; Leonard Clear solid topical deodorant compositions comprising a water-insoluble ester of a water-soluble acid
JP3749279B2 (ja) 1995-03-01 2006-02-22 日産化学工業株式会社 爪用抗真菌剤
NZ305784A (en) 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
RU2197964C2 (ru) 1995-04-12 2003-02-10 Дзе Проктер Энд Гэмбл Компани Фармацевтическая композиция, композиция стандартной лекарственной формы и способ лечения злокачественных новообразований, опухолей и вирусных инфекций
US6413539B1 (en) 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5811510A (en) 1995-04-14 1998-09-22 General Hospital Corporation Biodegradable polyacetal polymers and methods for their formation and use
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
JPH11506740A (ja) 1995-06-07 1999-06-15 アルカームズ コントロールド セラピューティックス，インコーポレイテッド ヒト成長ホルモンの徐放性組成物
FR2740335B1 (fr) 1995-10-26 1997-12-19 Oreal Utilisation de sel de lanthanide, de lithium, d'etain, de zinc, de manganese ou d'yttrium comme antagoniste de substance p
US5648389A (en) 1995-10-27 1997-07-15 Medicis Pharmaceutical, Inc. Compositions for the treatment of dermatological disorders and methods for their use
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6008173A (en) 1995-11-03 1999-12-28 Colgate-Palmolive Co. Bar composition comprising petrolatum
US5696105A (en) 1996-03-14 1997-12-09 Hackler; Walter A. Antifungal nail composition
FR2756493B1 (fr) 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
US6207142B1 (en) 1997-04-14 2001-03-27 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a cationic agent
US6043063A (en) 1997-04-15 2000-03-28 Monsanto Company Methods of PHA extraction and recovery using non-halogenated solvents
US5894020A (en) 1997-04-18 1999-04-13 Concha; Jose Soap composition containing antifungal agent
US20040102358A1 (en) 1997-05-19 2004-05-27 Scivoletto Rosemarie Composition for treating skin conditions
US6123957A (en) 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US5993790A (en) 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
DE19836436A1 (de) 1997-08-20 1999-03-11 Akzo Nobel Nv Verfahren zur Herstellung von biologisch abbaubaren Fasern und Filamenten
AU750809B2 (en) 1997-09-26 2002-07-25 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US5947956A (en) 1997-11-04 1999-09-07 Karell; Manuel Leon Laser apparatus for making holes and etchings
JP2001523273A (ja) 1998-02-09 2001-11-20 マクロケム・コーポレーシヨン 抗真菌性爪ラッカーおよびそれの使用方法
US6727401B1 (en) 1998-02-12 2004-04-27 Watson Pharmaceuticals, Inc. Pressure sensitive adhesive matrix patch for the treatment of onychomycosis
US6231840B1 (en) 1998-02-13 2001-05-15 Carol J. Buck Compositions and methods for the topical treatment of nail fungi conditions
CZ303404B6 (cs) 1998-02-23 2012-08-29 Massachusetts Institute Of Technology Kompozice degradovatelného polymeru s tvarovou pametí a predmet z nej vyrobený
EP1071413B1 (en) 1998-04-17 2004-06-16 Bertek Pharmaceuticals, Inc. Topical formulations for the treatment of nail fungal diseases
US20030007939A1 (en) 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US6309374B1 (en) 1998-08-03 2001-10-30 Insite Vision Incorporated Injection apparatus and method of using same
US6264927B1 (en) 1998-08-27 2001-07-24 Elmer P. Monahan Topical solution and method for the treatment of nail fungus
US6159977A (en) 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
US6270472B1 (en) 1998-12-29 2001-08-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Apparatus and a method for automatically introducing implants into soft tissue with adjustable spacing
US6221903B1 (en) 1999-01-11 2001-04-24 University And College Of Nevada, Reno Amiodarone as an antifungal agent
US6517863B1 (en) 1999-01-20 2003-02-11 Usbiomaterials Corporation Compositions and methods for treating nails and adjacent tissues
US6344190B1 (en) 1999-02-08 2002-02-05 Board Of Trustees Of Michigan State University Method and compositions for treatment of fungal nail disease
KR100372751B1 (ko) 1999-11-16 2003-02-17 한국과학기술원 생체조직공학용 다공성 생분해성 고분자 지지체의 제조방법
ATE368728T1 (de) 1999-03-18 2007-08-15 Korea Advanced Inst Sci & Tech Verfahren zur herstellung von porösen, biologisch abbaubaren und biokompatiblen polymeren stützgeweben zur gewebetechnologie
ATE270558T1 (de) 1999-08-26 2004-07-15 Ganeden Biotech Inc Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
KR100416242B1 (ko) 1999-12-22 2004-01-31 주식회사 삼양사 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US6386869B1 (en) 2000-02-18 2002-05-14 Peter J. Zegarelli Oral therapeutic delivery appliance
US6450938B1 (en) 2000-03-21 2002-09-17 Promex, Llc Brachytherapy device
US7074392B1 (en) 2000-03-27 2006-07-11 Taro Pharmaceutical Industries Limited Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
US20030021854A1 (en) 2001-04-23 2003-01-30 Burrell Robert Edward Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
WO2002022115A2 (en) 2000-09-14 2002-03-21 The Research Foundation Of State University Of New York At Stony Brook Methods and compositions for treating nail fungus
US6673756B2 (en) 2000-09-20 2004-01-06 Symrise Gmbh & Co. Kg Multiphase soaps
RU2196555C2 (ru) 2000-11-27 2003-01-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" Способ хирургического лечения открытоугольной глаукомы
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6676953B2 (en) 2001-01-26 2004-01-13 Don L. Hexamer Antifungal composition and method for human nails
US6878365B2 (en) 2001-03-10 2005-04-12 James Edward Brehove Topical application for treating toenail fungus
KR100354828B1 (ko) 2001-03-12 2002-10-05 주식회사 씨엠리서치 생분해성 폴리에스테르의 제조방법 및 그에 의해 제조된생분해성 폴리에스테르
GB0108082D0 (en) 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
EP1395626A1 (en) 2001-05-11 2004-03-10 AP Pharma, Inc. Peg-poe, peg-poe-peg, and poe-peg-poe block copolymers
US6664292B2 (en) 2001-06-04 2003-12-16 Mark H. Bogart Methods for the treatment of nail fungus and other microbial and mycotic conditions and compositions useful therefor
US7615234B2 (en) 2001-09-11 2009-11-10 Glide Pharmaceutical Technologies Limited Drug delivery technology
US20030118649A1 (en) 2001-10-04 2003-06-26 Jinming Gao Drug delivery devices and methods
US20030130225A1 (en) 2001-10-16 2003-07-10 Nawaz Ahmad Novel methods of treating local fungal and bacterial infections
CA2468539C (en) 2001-10-22 2013-01-08 Michael A. Repka Delivery of medicaments to the nail
US20030207971A1 (en) 2001-11-27 2003-11-06 React Of Delafield Llc Emollient gel
US7074426B2 (en) 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US6846837B2 (en) 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20030049307A1 (en) 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
US8404751B2 (en) 2002-09-27 2013-03-26 Hallux, Inc. Subunguicide, and method for treating onychomycosis
US20070014743A1 (en) * 2002-09-27 2007-01-18 Birnbaum Jay E Subunguicide, and method for treating onychomycosis
US7135194B2 (en) 2002-09-27 2006-11-14 Birnbaum Jay E Subunguicide, and method for treating onychomycosis
CA2511512C (en) 2002-12-27 2013-10-29 Chiron Corporation Immunogenic compositions containing phospholipid
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
DE602004021253D1 (de) 2003-03-21 2009-07-09 Nexmed Holdings Inc Antimykotischer nagellack und anwendungsverfahren
EP1607042A4 (en) 2003-03-27 2008-06-11 Terumo Corp HUMORETNAHME INSTRUMENT AND METHOD FOR HUMOR TAKING
US7214206B2 (en) 2003-04-03 2007-05-08 Valera Pharmaceuticals, Inc. Implanting device and method of using same
AU2004313245B2 (en) 2003-12-30 2011-04-14 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents, preferably a GNRH
US7588559B2 (en) 2004-07-01 2009-09-15 W&H Dentalwerk Bürmoos GmbH Injection systems
US7395790B2 (en) 2004-11-18 2008-07-08 S&S Cycle, Inc. Reed valve breather for evolution engine
US20060112503A1 (en) 2004-11-29 2006-06-01 The Procter & Gamble Company Solid personal care composition
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
AU2005314426A1 (en) 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
RU2361628C2 (ru) 2005-01-24 2009-07-20 Н.В. Органон Аппликатор для введения имплантата
CA2498623A1 (en) 2005-02-18 2006-08-18 Qlt Inc. Treatment of onychomycosis
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
EP2979699A1 (en) 2005-04-15 2016-02-03 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
WO2007084230A2 (en) 2005-12-13 2007-07-26 William Krause Automated biopsy and delivery device
DE102006018827A1 (de) 2006-04-22 2007-10-31 Bayer Healthcare Ag Applikator mit auswechselbarem Behälter
US20080261986A1 (en) 2007-03-30 2008-10-23 Friden Phillip M Pharmaceutical formulations for iontophoretic delivery of an anti-fungal drug
EP2896421A1 (en) 2007-04-20 2015-07-22 Jennifer Barbour Ergonomic syringe
US20080287912A1 (en) 2007-05-14 2008-11-20 Horrigan Corporation Method, Device And Formulation For The Treatment Of Nail Disorders
WO2009035567A2 (en) 2007-09-07 2009-03-19 Qlt Plug Delivery, Inc Insertion and extraction tools for lacrimal implants
US8221358B2 (en) 2007-11-20 2012-07-17 Warsaw Orthopedic, Inc. Devices and methods for delivering drug depots to a site beneath the skin
EP2501433A1 (en) * 2009-11-20 2012-09-26 Talima Therapeutics, Inc. Devices for implanting compositions and methods and kits therefor
CA2785549A1 (en) * 2009-12-22 2011-07-21 Talima Therapeutics, Inc. Antifungal therapy
CA2904703A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit

Also Published As

Publication number Publication date
CA2904703A1 (en) 2014-10-02
US20150238744A1 (en) 2015-08-27
EP2968886A1 (en) 2016-01-20
WO2014159060A1 (en) 2014-10-02
AU2014241396A1 (en) 2015-09-17
JP2016514024A (ja) 2016-05-19
US9498612B2 (en) 2016-11-22
CL2015002560A1 (es) 2017-04-28
US20170036004A1 (en) 2017-02-09
RU2015143995A (ru) 2017-04-20
BR112015022025A2 (pt) 2017-07-18
US10456568B2 (en) 2019-10-29
US20140276477A1 (en) 2014-09-18
CN105377355A (zh) 2016-03-02
US9375558B2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
PE20200494A1 (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson
BR112016029334A2 (pt) produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos
PL3377637T3 (pl) Kompozycje do stosowania w sposobach leczenia ran, zaburzeń i chorób skóry
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112018005110A2 (pt) Composição emoliente e sua utilização cosmética, composição cosmética, dermatológica ou farmacêutica e sua utilização cosmética e processo de tratamento cosmético da pele
BR112017008628A2 (pt) terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit
EP4349414A3 (en) Methods and formulations for transdermal administration
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
BR112017008344A2 (pt) extrato, uso de um extrato, e, composição cosmética ou dermofarmacêutica.
AU2018295515A1 (en) Compounds useful for the treatment and/or care of the skin, hair, nails and/or mucous membranes
EA201692334A1 (ru) Кортикостероидные композиции для местного применения
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
BR112015010772A2 (pt) composição de enxágue tópica, uso de uma composição e método para tratar ou melhorar a pele de um indivíduo contra a acne
ZA201902275B (en) Topical dressing composition for the treatment of damaged skin tissue
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
BR112017019829A2 (pt) antagonista do receptor nk-3, para o tratamento terapêutico ou cosmético de gordura corporal em excesso
BR112017007748A2 (pt) “composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
BR112015022025A8 (pt) composição e uso de um agente ativo
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
BR112016015997A2 (pt) ?composições farmacêuticas que compreendem 15- hepe e métodos para tratar asma e distúrbios pulmonares com o uso das mesmas?
BR112017027897A2 (pt) usos terapêuticos das formulações de berberina
BR112014031706A2 (pt) composição farmacêutica oral; forma de composição farmacêutica oral; método de redução de efeito de alimento de itraconazol em um indivíduo; método de redução de variabilidade em um mesmo indivíduo de itraconazol; método de redução de variabilidade entre indivíduos de itraconazol; método de tratamento de onicomicose; método de tratamento de uma doença ou afecção e método de tratamento de câncer
BR112016030275A2 (pt) Métodos para tratamento e redução dos sintomas da síndrome mão-pé (eritrodisestesia palmo-plantar)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2556 DE 31/12/2019.